Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05120232 · ClinicalTrials.gov registry record · NA

Flourishing and Virtue in Cognitive-Behavioral Therapy for Anxiety and Depressive Disorders

A NA study of Anxiety Disorders and Depressive Disorder, sponsored by Boston University Charles River Campus.

Completed
Registry status
NA
Development phase
125
Enrollment target
1
Study location

NCT05120232 is a NA study of Anxiety Disorders and Depressive Disorder that has completed, run by Boston University Charles River Campus. The registered enrollment target is 125 participants, below the 1,138-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05120232, a NA study of Anxiety Disorders and Depressive Disorder, has completed, sponsored by Boston University Charles River Campus.

COMPLETED
Registry status
NA
Development phase
125 participants
Enrollment target
1
Study location

Study Summary

This two phase study is testing an online version of a transdiagnostic, cognitive behavioral therapy, against a modified version of that therapy emphasizing positive affect. The first phase of the trial will focus on content development for the modified therapy and the second phase will be a randomized control trial comparing the two.

Interventions

  • BEHAVIORAL Unified Protocol
  • BEHAVIORAL Modified Unified Protocol (UP+)

Study Locations (1)

Massachusetts

  • Center for Anxiety and Related Disorders - Boston University - Boston

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2021-03-08
Est. Completion 2024-01-16
Phase NA

What the Registry Record Tells You About NCT05120232

The ClinicalTrials.gov registry entry for NCT05120232 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,138-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (89% lower). The listed sponsor is Boston University Charles River Campus, which has 104 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Anxiety Disorders appearing as the primary indexed condition, and to 2 interventions - of which Unified Protocol is the first listed.

NCT05120232 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05120232 about?

NCT05120232 is a clinical study titled "Flourishing and Virtue in Cognitive-Behavioral Therapy for Anxiety and Depressive Disorders". This two phase study is testing an online version of a transdiagnostic, cognitive behavioral therapy, against a modified version of that therapy emphasizing positive affect. The first phase of the trial will focus on content development for the modified therapy and the second phase will be a randomi...

What is the current status of trial NCT05120232?

This trial is currently completed. It is a NA study. The enrollment target is 125 participants. The study started on 2021-03-08. Estimated completion is 2024-01-16.

What conditions does trial NCT05120232 study?

This clinical trial studies the following conditions: Anxiety Disorders, Depressive Disorder.

What interventions are being tested in trial NCT05120232?

The interventions under investigation include: Unified Protocol (BEHAVIORAL), Modified Unified Protocol (UP+) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05120232?

This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05120232 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.